Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Inclusion Criteria:

One of the following diagnoses with histological confirmation by the Pathology Department at H. Lee Moffitt Cancer Center:
Acute Lymphocytic Leukemia (ALL) in complete remission 1 (CR1) with t(9:22) or t(4:11), or any ALL beyond CR1
Acute Myelogenous Leukemia (AML) with high risk cytogenetics in CR1 as defined by Bloomfield any AML beyond CR1
Myelodysplastic Syndrome (MDS) with International Prognostic Scoring System (IPSS) score > 1
Chronic myelomonocytic leukemia (CMML)
Chronic Myelogenous Leukemia (CML) with Imatinib-refractory chronic phase, or beyond chronic phase by morphology or cytogenetics
Myelofibrosis
Severe aplastic anemia
Chemosensitive Non-Hodgkin's lymphoma and Hodgkin's disease that are not candidate to autologous transplant due to prior autologous transplantation
Multiple Myeloma patient not candidate for autologous stem cell transplantation
Karnofsky performance status ≥ 70% (adult)
Normal organ and marrow function as defined below:
Hepatic: Total bilirubin must be less than or equal to 2mg/dL (Gilbert and other syndromes with increased indirect bilirubin are allowed); serum transaminases must be less than two times the upper limit of normal
Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) (corrected for Hgb), forced expiratory volume-one second (FEV1), forced vital capacity (FVC) must be greater than 50% predicted
Cardiac: Left ventricular ejection fraction at rest must be greater than 50%
Renal: Creatinine clearance (measured or calculated) must be equal or greater than 50 ml/min/1.73m^2

Exclusion Criteria:

Anti thymocyte globulin (ATG) or anti T cell therapy in prior 45 days
Splenectomized patients;
A positive pregnancy test administered to all females of childbearing potential prior to allogeneic stem cell transplant
Inability to comply with follow up as determined by the patient's physician
HIV-I/II infection prior to hematopoietic stem cell (HSC) transplantation, confirmed by nucleic acid test (NAT)
Uncontrolled bacterial or fungal infection
History of documented invasive aspergillosis or cytomegalovirus (CMV) pneumonia
Presence of any of the following comorbid conditions:
History of myocardial infarction
Congestive heart failure (even if symptomatically controlled)
Peripheral vascular disease (including intermittent claudication or history of bypass for arterial insufficiency)
Untreated thoracic or abdominal aneurysm (6cm or more)
History of any cerebrovascular accident including transient ischemic attacks
Dementia
History of peptic ulcer disease requiring treatment
Connective tissue/rheumatologic disorders
Diabetes unless being managed with dietary changes only
Hemiplegia/paraplegia
History of solid tumor excluding skin or cervical carcinoma after curative resection